IDXX vs. TAK: A Head-to-Head Stock Comparison

Updated on August 25, 2025

Here’s a clear look at IDXX and TAK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

IDXX is a standard domestic listing, while TAK trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.

Symbol	IDXX	TAK
Company Name	IDEXX Laboratories, Inc.	Takeda Pharmaceutical Company Limited
Country	United States	Japan
GICS Sector	Health Care	Health Care
GICS Industry	Health Care Equipment & Supplies	Pharmaceuticals
Market Capitalization	51.19 billion USD	49.05 billion USD
Exchange	NasdaqGS	NYSE
Listing Date	June 21, 1991	January 5, 2010
Security Type	Common Stock	ADR

Historical Performance

This chart compares the performance of IDXX and TAK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

IDXX vs. TAK: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	IDXX	TAK
5-Day Price Return	-2.16%	3.56%
13-Week Price Return	22.65%	10.08%
26-Week Price Return	39.17%	9.06%
52-Week Price Return	28.75%	5.51%
Month-to-Date Return	19.75%	7.43%
Year-to-Date Return	54.76%	7.92%
10-Day Avg. Volume	0.52M	4.64M
3-Month Avg. Volume	0.68M	4.43M
3-Month Volatility	60.53%	14.70%
Beta	1.58	0.36

Profitability

Return on Equity (TTM)

IDXX

64.42%

Health Care Equipment & Supplies Industry

Max: 34.53%
Q3: 19.38%
Median: 9.52%
Q1: 4.86%
Min: -7.58%

IDXX’s Return on Equity of 64.42% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

TAK

1.48%

Pharmaceuticals Industry

Max: 38.59%
Q3: 19.84%
Median: 11.90%
Q1: 5.63%
Min: -9.96%

TAK’s Return on Equity of 1.48% is in the lower quartile for the Pharmaceuticals industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.

IDXX vs. TAK: A comparison of their Return on Equity (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

IDXX

24.41%

Health Care Equipment & Supplies Industry

Max: 23.34%
Q3: 13.06%
Median: 9.53%
Q1: 5.96%
Min: -3.87%

IDXX’s Net Profit Margin of 24.41% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.

TAK

2.36%

Pharmaceuticals Industry

Max: 34.51%
Q3: 17.73%
Median: 12.12%
Q1: 5.99%
Min: -7.73%

Falling into the lower quartile for the Pharmaceuticals industry, TAK’s Net Profit Margin of 2.36% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.

IDXX vs. TAK: A comparison of their Net Profit Margin (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

IDXX

31.09%

Health Care Equipment & Supplies Industry

Max: 29.44%
Q3: 17.80%
Median: 13.95%
Q1: 8.73%
Min: -3.56%

IDXX’s Operating Profit Margin of 31.09% is exceptionally high, placing it well above the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.

TAK

7.48%

Pharmaceuticals Industry

Max: 41.53%
Q3: 23.00%
Median: 16.24%
Q1: 9.24%
Min: -6.94%

TAK’s Operating Profit Margin of 7.48% is in the lower quartile for the Pharmaceuticals industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.

IDXX vs. TAK: A comparison of their Operating Profit Margin (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Profitability at a Glance

Symbol	IDXX	TAK
Return on Equity (TTM)	64.42%	1.48%
Return on Assets (TTM)	29.89%	0.72%
Net Profit Margin (TTM)	24.41%	2.36%
Operating Profit Margin (TTM)	31.09%	7.48%
Gross Profit Margin (TTM)	61.54%	65.51%

Financial Strength

Current Ratio (MRQ)

IDXX

1.11

Health Care Equipment & Supplies Industry

Max: 4.90
Q3: 3.05
Median: 2.14
Q1: 1.49
Min: 0.86

IDXX’s Current Ratio of 1.11 falls into the lower quartile for the Health Care Equipment & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

TAK

1.01

Pharmaceuticals Industry

Max: 4.49
Q3: 2.77
Median: 1.74
Q1: 1.26
Min: 0.11

TAK’s Current Ratio of 1.01 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

IDXX vs. TAK: A comparison of their Current Ratio (MRQ) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

IDXX

0.76

Health Care Equipment & Supplies Industry

Max: 1.49
Q3: 0.71
Median: 0.45
Q1: 0.14
Min: 0.00

IDXX’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 0.76. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

TAK

0.65

Pharmaceuticals Industry

Max: 2.44
Q3: 1.07
Median: 0.42
Q1: 0.11
Min: 0.00

TAK’s Debt-to-Equity Ratio of 0.65 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

IDXX vs. TAK: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

IDXX

49.24

Health Care Equipment & Supplies Industry

Max: 58.29
Q3: 25.56
Median: 9.06
Q1: 3.60
Min: -28.92

IDXX’s Interest Coverage Ratio of 49.24 is in the upper quartile for the Health Care Equipment & Supplies industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

TAK

2.05

Pharmaceuticals Industry

Max: 103.95
Q3: 44.18
Median: 9.83
Q1: 2.82
Min: -42.71

In the lower quartile for the Pharmaceuticals industry, TAK’s Interest Coverage Ratio of 2.05 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.

IDXX vs. TAK: A comparison of their Interest Coverage Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

Symbol	IDXX	TAK
Current Ratio (MRQ)	1.11	1.01
Quick Ratio (MRQ)	0.75	0.52
Debt-to-Equity Ratio (MRQ)	0.76	0.65
Interest Coverage Ratio (TTM)	49.24	2.05

Growth

Revenue Growth

IDXX vs. TAK: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

IDXX vs. TAK: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

IDXX

0.00%

Health Care Equipment & Supplies Industry

Max: 4.05%
Q3: 1.76%
Median: 0.71%
Q1: 0.00%
Min: 0.00%

IDXX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

TAK

4.23%

Pharmaceuticals Industry

Max: 6.98%
Q3: 3.32%
Median: 2.13%
Q1: 0.14%
Min: 0.00%

With a Dividend Yield of 4.23%, TAK offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.

IDXX vs. TAK: A comparison of their Dividend Yield (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

IDXX

0.00%

Health Care Equipment & Supplies Industry

Max: 160.00%
Q3: 72.47%
Median: 27.49%
Q1: 0.00%
Min: 0.00%

IDXX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

TAK

138.69%

Pharmaceuticals Industry

Max: 165.20%
Q3: 90.59%
Median: 49.13%
Q1: 28.91%
Min: 0.00%

TAK’s Dividend Payout Ratio of 138.69% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.

IDXX vs. TAK: A comparison of their Dividend Payout Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Dividend at a Glance

Symbol	IDXX	TAK
Dividend Yield (TTM)	0.00%	4.23%
Dividend Payout Ratio (TTM)	0.00%	138.69%

Valuation

Price-to-Earnings Ratio (TTM)

IDXX

51.66

Health Care Equipment & Supplies Industry

Max: 73.48
Q3: 51.69
Median: 34.31
Q1: 25.74
Min: 11.47

IDXX’s P/E Ratio of 51.66 is within the middle range for the Health Care Equipment & Supplies industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

TAK

66.26

Pharmaceuticals Industry

Max: 42.51
Q3: 26.88
Median: 19.11
Q1: 15.12
Min: 0.00

At 66.26, TAK’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

IDXX vs. TAK: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

IDXX

12.61

Health Care Equipment & Supplies Industry

Max: 9.53
Q3: 5.26
Median: 3.39
Q1: 2.13
Min: 0.00

With a P/S Ratio of 12.61, IDXX trades at a valuation that eclipses even the highest in the Health Care Equipment & Supplies industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

TAK

1.56

Pharmaceuticals Industry

Max: 7.55
Q3: 4.54
Median: 2.11
Q1: 1.52
Min: 0.00

TAK’s P/S Ratio of 1.56 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

IDXX vs. TAK: A comparison of their Price-to-Sales Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

IDXX

29.57

Health Care Equipment & Supplies Industry

Max: 10.85
Q3: 5.98
Median: 3.48
Q1: 2.43
Min: 0.69

At 29.57, IDXX’s P/B Ratio is at an extreme premium to the Health Care Equipment & Supplies industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

TAK

1.01

Pharmaceuticals Industry

Max: 9.78
Q3: 4.96
Median: 2.23
Q1: 1.46
Min: 0.60

TAK’s P/B Ratio of 1.01 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

IDXX vs. TAK: A comparison of their Price-to-Book Ratio (MRQ) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Valuation at a Glance

Symbol	IDXX	TAK
Price-to-Earnings Ratio (TTM)	51.66	66.26
Price-to-Sales Ratio (TTM)	12.61	1.56
Price-to-Book Ratio (MRQ)	29.57	1.01
Price-to-Free Cash Flow Ratio (TTM)	65.76	10.08